Acta Medica Okayama 75巻 1号
2021-02 発行
Senoo, Mayumi
Department of Internal Medicine, Diabetes Center, Okayama Saiseikai General Hospital
Tone, Atsuhito
Department of Internal Medicine, Diabetes Center, Okayama Saiseikai General Hospital
Imai, Yusuke
Department of Internal Medicine, Diabetes Center, Okayama Saiseikai General Hospital
Watanabe, Satoko
Department of Internal Medicine, Diabetes Center, Okayama Saiseikai General Hospital
Kaneto, Mitsuhiro
Department of Internal Medicine, Diabetes Center, Okayama Saiseikai General Hospital
Shimomura, Yasuyuki
Department of Internal Medicine, Diabetes Center, Okayama Saiseikai General Hospital
Teshigawara, Sanae
Department of Internal Medicine, Diabetes Center, Okayama Saiseikai General Hospital
Kaken ID
Nakatou, Tatsuaki
Department of Internal Medicine, Diabetes Center, Okayama Saiseikai General Hospital
A 43-year-old male with type 2 diabetes, under treatment with 5 mg/day of dapagliflozin, was referred to our hospital with upper left abdominal pain and marked hypertriglyceridemia (triglycerides [TGs], 5,960 mg/dl). He was also on a low-carbohydrate diet that promoted ketosis under sodium glucose cotransporter 2 (SGLT2) inhibitor administration. Polyacrylamide gel electrophoresis revealed a remarkable increase in very-low-den-sity lipoprotein, a TG-rich lipoprotein particle synthesized in the liver using free fatty acids derived from adi-pose tissue. Although SGLT2 inhibitors generally improve the lipid profile, under certain conditions such as a low-carbohydrate diet, they may adversely exacerbate the lipid profile via ketosis.
sodium glucose cotransporter 2 inhibitor
dyslipidemia
hypertriglyceridemia
type 2 diabetes mellitus